SLC5A2 and type 2 diabetes mellitus: The US Food and Drug Administration (FDA) has approved 4 SGLT-2 inhibitors for the improvement of glycemic control in patients with T2DM and preserved kidney function: empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin [12,13].